As of Feb 16
| +0.60 / +3.35%|
The 1 analysts offering 12-month price forecasts for Cellular Biomedicine Group Inc have a median target of 18.00, with a high estimate of 18.00 and a low estimate of 18.00. The median estimate represents a -2.70% decrease from the last price of 18.50.
The current consensus among 1 polled investment analysts is to Hold stock in Cellular Biomedicine Group Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.